⚙
AI-generated summary
by qwen3.7-flash, 2026-11-06
ⓘ
This paper reviews adenomyosis literature and presents a homeopathic case report, describing the condition's clinical features, diagnostic imaging methods, and treatment options ranging from hormonal suppression to hysterectomy.
⚙
AI-generated deep summary
by qwen3.7-flash, 2026-11-06
· read from full text
ⓘ
This paper provides a literature overview of adenomyosis, defining it as a benign uterine condition where endometrial tissue grows within the myometrium, distinct from but often co-occurring with endometriosis. It outlines that while many patients are asymptomatic, common symptoms include heavy menstrual bleeding and pelvic pain, with diagnosis typically confirmed via ultrasonography or MRI in women aged 40 to 50. The authors present a homeopathic case report using Sepia officinalis and discuss standard treatments ranging from hormonal suppression to hysterectomy for refractory cases. This paper is centrally about adenomyosis, serving as both a clinical review of the condition and a specific homeopathic treatment case study.
Abstract
Adenomyosis is a benign uterine condition characterized by the presence of endometrial glands and stroma within the myometrium. “A substantial proportion of patients may be asymptomatic, but the rest may present with heavy menstrual bleeding, pelvic pain, or infertility. Heavy menstrual bleeding is the most common symptom. Adenomyosis is distinct from endometriosis (the presence of endometrial glands outside of the uterus), but the two conditions often occur simultaneously. Risk factors for developing adenomyosis include increasing age, parity, and history of uterine procedures. Most patients are diagnosed from 40 to 50 years of age, but younger patients with infertility are increasingly being diagnosed with adenomyosis as imaging modalities improve. Diagnosis of adenomyosis begins with clinical suspicion and is confirmed with transvaginal ultrasonography and pelvic magnetic resonance imaging. Treatment of adenomyosis typically starts with hormonal menstrual suppression. Levonorgestrel-releasing intrauterine systems have shown some effectiveness. Patients with adenomyosis may ultimately have a hysterectomy if symptoms are not controlled with medical therapy.
Full text
3,316 characters
· extracted from
oa-html
· click to expand
Adenomyosis: An Overview of Literature and Homeopathic Case Report
DOI:
https://doi.org/10.68050/JAMS.2026.899Keywords:
Adenomyosis, Heavy Menstrual Bleeding, Dysmenorrhoea, Individualised Homoeopathic Treatment, Sepia officinalis, Homoeopathic Case Report, Ultrasonographic Evaluation, Repertorisation.Abstract
Adenomyosis is a benign uterine condition characterized by the presence of endometrial glands and stroma within the myometrium. “A substantial proportion of patients may be asymptomatic, but the rest may present with heavy menstrual bleeding, pelvic pain, or infertility. Heavy menstrual bleeding is the most common symptom. Adenomyosis is distinct from endometriosis (the presence of endometrial glands outside of the uterus), but the two conditions often occur simultaneously. Risk factors for developing adenomyosis include increasing age, parity, and history of uterine procedures. Most patients are diagnosed from 40 to 50 years of age, but younger patients with infertility are increasingly being diagnosed with adenomyosis as imaging modalities improve. Diagnosis of adenomyosis begins with clinical suspicion and is confirmed with transvaginal ultrasonography and pelvic magnetic resonance imaging. Treatment of adenomyosis typically starts with hormonal menstrual suppression. Levonorgestrel-releasing intrauterine systems have shown some effectiveness. Patients with adenomyosis may ultimately have a hysterectomy if symptoms are not controlled with medical therapy.
References
1. Haththotuwa R. DC Dutta's Textbook of Gynecology. Journal of South Asian Federation of Obstetrics and Gynaecology. 2025 Feb 3;16(S3):S275-.
2. Bulun SE, Yildiz S, Adli M, Wei JJ. Adenomyosis pathogenesis: insights from next-generation sequencing. Human reproduction update. 2021 Nov 1;27(6):1086-97.
3. Zhai J, Vannuccini S, Petraglia F, Giudice LC. Adenomyosis: mechanisms and pathogenesis. InSeminars in reproductive medicine 2020 May (Vol. 38, No. 02/03, pp. 129-143). Thieme Medical Publishers, Inc..
4. Zhai J, Vannuccini S, Petraglia F, Giudice LC. Adenomyosis: mechanisms and pathogenesis. Semin Reprod Med. 2020;38(2-03):129-143. doi:10.1055/s-0040-1716687.
5. MUSA Group. Consensus on sonographic features of adenomyosis: updated MUSA criteria.
6. European Society of Human Reproduction and Embryology. ESHRE guideline on the management of women with adenomyosis.
7. Becker CM, Ebert AD, Kiesel L, et al. ESHRE guideline: management of women with adenomyosis.
8. Harmsen MJ, Van den Bosch T, de Leeuw RA, Dueholm M, Exacoustos C, Valentin L, et al. Consensus on revised definitions of Morphological Uterus Sonographic Assessment (MUSA) features of adenomyosis: results of modified Delphi procedure.
9. Mind Technologies Private Limited. Hompath Zomeo: homeopathy software [Internet]. Mumbai: Mind Technologies Private Limited; 2026 [cited 2026 Aug 30]. Available from:
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Author(s)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Articles published in the Journal of Advanced Multidisciplinary Studies (JAMS) are licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), unless otherwise stated. Authors retain copyright of their work and grant JAMS the right of first publication.
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.